Skip to content

DaVita DVA Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

UnitedHealth Group logo
UnitedHealth GroupUNH
Baxter International logo
Baxter InternationalBAX
IQVIA logo
IQVIAIQV

Other financials

Income statement

See full
Revenue$3.4B+6.0%
Operating income$481.9M+9.8%
Net income$197.5M+21.2%
EPS (diluted)$2.87+43.5%

Balance sheet

See full
Cash & equivalents$726.4M+38.5%
Total debt$13.3B+6.7%
Total equity-$755.5M-183%
Total assets$17.5B+2.2%

Cash flow

See full
Operating cash flow$320.8M+78.2%
CapEx$102.0M-28.8%
Free cash flow$218.8M+495%

Valuation

See full
Market cap$13.34B-16.0%
Enterprise value$25.95B-5.5%
P/E17.1×-1.4×
P/S-0.3×

Profitability

See full
Operating margin15.1%-0.7pp
Net margin5.6%-1.0pp
FCF margin10.8%-2.8pp

Returns & leverage

See full
Return on equity159.1%+80.9pp
Debt / equity103.6×+92.8×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by DaVita in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: DaVita’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about DaVita's common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DaVita's common stock, shares authorized (in shares)?
DaVita (DVA) reported common stock, shares authorized (in shares) of $450M in Q1 2026.
How has DaVita's common stock, shares authorized (in shares) changed year-over-year?
DaVita's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $450M to $450M.
What is the long-term trend for DaVita's common stock, shares authorized (in shares)?
Over 5 years (2020 to 2025), DaVita's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $450M to $450M.